– USA, CA – Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company today announced the appointment of Tom Wiggans as CEO and Chair of the Board of Directors.
Dr. Uri Lopatin will remain on the Board of Directors and continue to play an active role in the research and development activities as Chief Scientific & Strategic Advisor.
In addition, Mark Auerbach will transition from the Chairman role to a member of the Board of Directors.
“It’s my privilege to welcome Tom as Pardes Biosciences’ new Chief Executive Officer and Chairman of its Board of Directors. Pardes has moved at “warp speed” from a discovery company to a clinical stage company. As we continue to evolve, Tom’s expertise in growing and leading biotech companies through development and commercialization makes him the perfect successor,” said Founder and former CEO, Dr. Uri Lopatin.
About Thomas G. Wiggans
Tom Wiggans has 40 years of experience in the biopharmaceutical industry, including over 25 years of CEO leadership. Mr. Wiggans most recently served as CEO and Chairman of the Board of Directors of Dermira, which he co-founded in 2010 until its acquisition by Eli Lilly in 2020 for $1.1 billion. Before founding Dermira, Mr. Wiggans served as CEO and Chairman of the Board of Directors of Peplin, Inc. until its acquisition by LEO Pharma A/S in 2009. Previously, he served as CEO and Chairman of the Board of Directors of Connetics Corporation through its acquisition by Stiefel Laboratories in 2006. Mr. Wiggans also served as President and COO of CytoTherapeutics Inc. and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. He began his career in the industry with Eli Lilly and Company.
“Pardes has made tremendous progress developing PBI-0451 and advancing an exciting anti-viral platform in a very short period. I commend the Pardes team for their commitment, expertise, and accomplishments,” said Chairman and CEO, Tom Wiggans. “The COVID pandemic has had a profound impact on our planet, inflicting terrible human and economic consequences. Yet vaccines and therapies have been developed in record time, helping us avoid a pandemic that could have been much worse. We must continue to accelerate these efforts. I thank the people working to ensure that we have better treatments for current patients and are better prepared for future pandemics. I am honored to join the Pardes team and its battle against COVID, and I look forward to working with the executive team and the Pardes board to develop the operational capabilities and strategic relationships to help bring these potential therapies to patients as quickly as possible.”
Mr. Wiggans is currently on the Board of Directors of Annexon, Inc., Cymabay Therapeutics Inc., and Forma Therapeutics Holdings, Inc. He has previously served on the Board of Directors for various industry organizations, educational institutions, and both private and public companies, including service on the board of Onyx Pharmaceuticals, Sangamo Biosciences, and Somaxon Pharmaceuticals, Inc.
He holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.
About Pardes Biosciences, Inc.
Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates.
For more information: https://www.pardesbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
